Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
62 studies found for:    canakinumab
Show Display Options
Rank Status Study
1 Completed Efficacy and Safety of Canakinumab in Schnitzler Syndrome
Condition: Schnitzler Syndrome
Intervention: Drug: Canakinumab
2 Completed
Has Results
Canakinumab Study in Individuals With Newly Diagnosed Type 1 Diabetes
Conditions: Type 1 Diabetes;   Preservation of Insulin Secretion;   Newly Diagnosed Type 1 Diabetes;   Canakinumab in Type 1 Diabetes
Interventions: Drug: canakinumab (anti IL-1beta);   Drug: Placebo
3 Recruiting Canakinumab for Treatment of Adult Onset Still's Disease
Condition: Adult-Onset Still´s Disease
Interventions: Drug: Canakinumab;   Drug: Placebo
4 Completed Ilaris® in Urticarial Vasculitis - Investigation of Treatment Responses
Conditions: Urticaria;   Vasculitis
Intervention: Drug: canakinumab
5 Recruiting ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab
Condition: Systemic Juvenile Idiopathic Arthritis (SJIA)
Intervention: Drug: ACZ885 150 mg (Canakinumab)
6 Completed An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever.
Condition: Systemic Juvenile Idiopathic Arthritis
Intervention: Drug: Canakinumab
7 Active, not recruiting Study of Efficacy and Safety of Canakinumab in Japanese Patients With SJIA
Condition: Systemic Juvenile Idiopathic Arthritis
Intervention: Biological: Canakinumab
8 Completed Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients
Condition: Acute Gouty Arthritis
Intervention: Drug: Canakinumab 150mg in prefilled syringe
9 Completed Evaluate the Safety and Efficacy of Canakinumab in Pediatric Patients With Colchicine Intolerant or Colchicine Resistant Familial Mediterranean Fever (FMF)
Condition: Colchicine Resistant/Intolerant Familial Mediterranean Fever
Intervention: Drug: Canakinumab
10 Completed Efficacy and Safety of Canakinumab in Patients With Colchicine Resistant Familial Mediterranean Fever
Condition: Familial Mediterranean Fever
Intervention: Drug: Canakinumab
11 Active, not recruiting Ilaris® Effects in Schnitzler Syndrome (ILESCH)
Condition: Schnitzler Syndrome
Interventions: Drug: Canakinumab;   Drug: Placebo
12 Active, not recruiting a Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis Who Participated in the Study CACZ885G2301E1
Condition: Systemic Juvenile Idiopathic Arthritis
Intervention: Drug: canakinumab
13 Completed The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada
Condition: Cryopyrin Associated Periodic Syndrome
Intervention: Drug: canakinumab (company code: ACZ885D)
14 Completed Canakinumab for Pyoderma Gangrenosum
Condition: Pyoderma Gangrenosum
Intervention: Drug: Canakinumab
15 Recruiting Efficacy Study of Canakinumab to Treat Urticaria
Condition: Chronic Idiopathic Urticaria
Interventions: Drug: Canakinumab;   Drug: Placebo
16 Completed Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension Phase
Conditions: Cryopyrin-associated Periodic Syndromes;   Familial Cold Autoinflammatory Syndrome;   Muckle-Wells Syndrome;   Neonatal Onset Multisystem Inflammatory Disease
Intervention: Drug: canakinumab
17 Recruiting 1 Year Canakinumab Treatment in Behcet's Disease Patients With Neurologic or Vascular Involvement
Condition: Behcet Disease
Intervention: Drug: drug administration
18 Not yet recruiting Ilaris (Canakinumab) in Patient With Periodic Fever, Aphthous Stomatitis, Pharyngitis and Cervical Adenitis (PFAPA)
Condition: Periodic Fever
Intervention: Drug: Canakinumab
19 Completed Ilaris (Canakinumab) in the Schnitzler Syndrome
Condition: Schnitzler Syndrome
Intervention: Drug: Ilaris
20 Terminated Canakinumab to Treat Neonatal-Onset Multisystem Inflammatory Disease
Conditions: NOMID;   CINCA Syndrome
Intervention: Drug: Canakinumab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.